41335-32-4 Usage
Uses
Used in Enzymatic Assays:
1-NAPHTHYL-BETA-D-GALACTOPYRANOSIDE is used as a chromogenic substrate for detecting and quantifying beta-galactosidase activity in enzymatic assays. Its ability to produce a yellow-colored product upon enzyme cleavage allows for the accurate measurement of enzyme activity, which is essential for understanding biochemical processes and enzyme kinetics.
Used in Microbiology Experiments:
In microbiology, 1-NAPHTHYL-BETA-D-GALACTOPYRANOSIDE is used as a tool for studying gene expression and signal transduction pathways. Its role as a substrate for beta-galactosidase enables researchers to monitor the activity of this enzyme in various microorganisms, providing insights into their metabolic and regulatory mechanisms.
Used in Pharmaceutical Research and Drug Development:
1-NAPHTHYL-BETA-D-GALACTOPYRANOSIDE is used as a testing agent in pharmaceutical research and drug development. It helps evaluate the efficacy of enzyme inhibitors and potential therapeutic agents targeting beta-galactosidase. By measuring the enzyme activity in the presence of these agents, researchers can assess their inhibitory effects and potential as treatments for various diseases and conditions.
Used in Biochemical Research:
In biochemical research, 1-NAPHTHYL-BETA-D-GALACTOPYRANOSIDE is used as a research tool for studying the structure, function, and regulation of beta-galactosidase. Its ability to produce a visible product upon enzyme cleavage allows researchers to investigate the enzyme's catalytic properties, substrate specificity, and interactions with other biomolecules.
Used in Diagnostic Applications:
1-NAPHTHYL-BETA-D-GALACTOPYRANOSIDE is used as a diagnostic agent for detecting and measuring beta-galactosidase activity in clinical samples. Its sensitivity and specificity in detecting enzyme activity make it a valuable tool for diagnosing and monitoring diseases and conditions associated with altered beta-galactosidase levels.
Used in Educational Settings:
In educational settings, 1-NAPHTHYL-BETA-D-GALACTOPYRANOSIDE is used as a teaching aid for demonstrating enzyme activity and the principles of enzymatic reactions. Its visual output upon enzyme cleavage provides a clear and engaging way for students to understand the fundamentals of biochemistry and molecular biology.
Check Digit Verification of cas no
The CAS Registry Mumber 41335-32-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 4,1,3,3 and 5 respectively; the second part has 2 digits, 3 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 41335-32:
(7*4)+(6*1)+(5*3)+(4*3)+(3*5)+(2*3)+(1*2)=84
84 % 10 = 4
So 41335-32-4 is a valid CAS Registry Number.
InChI:InChI=1/C16H18O6/c17-8-12-13(18)14(19)15(20)16(22-12)21-11-7-3-5-9-4-1-2-6-10(9)11/h1-7,12-20H,8H2/t12-,13+,14+,15-,16-/m1/s1
41335-32-4Relevant academic research and scientific papers
COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS
-
Paragraph 0085; 0092; 0094; 0101, (2019/05/30)
The present invention is directed to various compounds, compositions, and methods for treating bacterial infections such as urinary tract infections.
Structure-based discovery of glycomimetic FmlH ligands as inhibitors of bacterial adhesion during urinary tract infection
Kalas, Vasilios,Hibbing, Michael E.,Maddirala, Amarendar Reddy,Chugani, Ryan,Pinkner, Jerome S.,Mydock-McGrane, Laurel K.,Conover, Matt S.,Janetka, James W.,Hultgren, Scott J.
, p. E2819 - E2828 (2018/03/27)
Treatment of bacterial infections is becoming a serious clinical challenge due to the global dissemination of multidrug antibiotic resistance, necessitating the search for alternative treatments to disarm the virulence mechanisms underlying these infections. Uropathogenic Escherichia coli (UPEC) employs multiple chaperone- usher pathway pili tipped with adhesins with diverse receptor specificities to colonize various host tissues and habitats. For example, UPEC F9 pili specifically bind galactose or N-acetylgalactosamine epitopes on the kidney and inflamed bladder. Using X-ray structureguided methods, virtual screening, and multiplex ELISA arrays, we rationally designed aryl galactosides and N-acetylgalactosaminosides that inhibit the F9 pilus adhesin FmlH. The lead compound, 29β-NAc, is a biphenyl N-acetyl-β-galactosaminoside with a Ki of ～90 nM, representing a major advancement in potency relative to the characteristically weak nature of most carbohydrate-lectin interactions. 29β-NAc binds tightly to FmlH by engaging the residues Y46 through edge-to-face π-stacking with its A-phenyl ring, R142 in a salt-bridge interaction with its carboxylate group, and K132 through watermediated hydrogen bonding with its N-acetyl group. Administration of 29β-NAc in a mouse urinary tract infection (UTI) model significantly reduced bladder and kidney bacterial burdens, and coadministration of 29β-NAc and mannoside 4Z269, which targets the type 1 pilus adhesin FimH, resulted in greater elimination of bacteria from the urinary tract than either compound alone. Moreover, FmlH specifically binds healthy human kidney tissue in a 29β-NAc-inhibitable manner, suggesting a key role for F9 pili in human kidney colonization. Thus, these glycoside antagonists of FmlH represent a rational antivirulence strategy for UPEC-mediated UTI treatment.
